The importance of pharmacogenomic guidance is shown by a systematic review of five studies (total n = 2900 patients, average age 67 years) of the effects of CYP2C19 variants on the outcomes of myocardial infarcts, revascularisation, stroke or death. The gene discussed is CYP2C19; the disease is Stroke.